Clinical Trials Browser

INDUSTRY × Esophageal Neoplasms × icotinib × Clear all

NCT01855854 2019-07-05

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms